Patient eligibility and trial design for the salvage therapy of advanced urothelial carcinoma

Clinical Genitourinary Cancer

Volumn 12, Issue 6, 2014, Pages 395-398

  Sonpavde, Guru ^a   Bellmunt, Joaquim ^b   Rosenberg, Jonathon E ^c   Regazzi, Ashley M ^c   Bajorin, Dean F ^c   Choueiri, Toni K ^d   Qu, Angela Q ^d   Niegisch, Guenter ^e   Albers, Peter ^e   Necchi, Andrea ^f   Di Lorenzo, Giuseppe ^g   Fougeray, Ronan ^h   Wong, Yu Ning ⁱ   Sridhar, Srikala S ^j   Ko, Yoo Joung ^k   Milowsky, Matthew I ^l   Galsky, Matthew D ^m   Pond, Gregory R ⁿ  

^a UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

^b HOSPITAL DEL MAR   (Spain)

^c MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^d DANA FARBER CANCER INSTITUTE   (United States)

^e HEINRICH HEINE UNIVERSITY   (Germany)

^f NATIONAL CANCER INSTITUTE   (Italy)

^g UNIVERSITY OF NAPLES FEDERICO II   (Italy)

^h INSTITUT DE RECHERCHE PIERRE FABRE   (France)

ⁱ FOX CHASE CANCER CENTER   (United States)

^j PRINCESS MARGARET HOSPITAL   (Canada)

^k DEPARTMENT OF RADIATION ONCOLOGY   (Canada)

^l UNIVERSITY OF NORTH CAROLINA   (United States)

^m MOUNT SINAI SCHOOL OF MEDICINE   (United States)

ⁿ MCMASTER UNIVERSITY   (Canada)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC METAL COMPLEX; ANTINEOPLASTIC AGENT;

ADVANCED CANCER; AGE; AGE DISTRIBUTION; CANCER CHEMOTHERAPY; CANCER PROGNOSIS; CANCER SURVIVAL; COMORBIDITY; DRUG SENSITIVITY; HUMAN; OVERALL SURVIVAL; PATIENT HISTORY OF CHEMOTHERAPY; PATIENT SELECTION; PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PROGRESSION FREE SURVIVAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; SALVAGE THERAPY; STUDY DESIGN; SYSTEMIC THERAPY; TRANSITIONAL CELL CARCINOMA; TREATMENT RESPONSE; CARCINOMA, TRANSITIONAL CELL; METHODOLOGY; PROCEDURES; URINARY BLADDER NEOPLASMS;

ANTINEOPLASTIC AGENTS; CARCINOMA, TRANSITIONAL CELL; CLINICAL TRIALS, PHASE II AS TOPIC; HUMANS; PATIENT SELECTION; RESEARCH DESIGN; SALVAGE THERAPY; URINARY BLADDER NEOPLASMS;

EID: 84922729773     PISSN: 15587673     EISSN: 19380682     Source Type: Journal    
DOI: 10.1016/j.clgc.2014.03.016     Document Type: Note

References (19)

1. Sonpavde G, Sternberg CN, Rosenberg JE, Hahn NM, Galsky MD, Vogelzang NJ. Second-line systemic therapy and emerging drugs for metastatic transitional-cell carcinoma of the urothelium. Lancet Oncol 2010; 11: 861-70
2. Bellmunt J, Theodore C, Demkov T, et al. Phase III trial of vinflunine plus best supportive care compared with best supportive care alone after a platinumcontaining regimen in patients with advanced transitional cell carcinoma of the urothelial tract. J Clin Oncol 2009; 27:4454-61
3. Necchi A, Mariani L, Zaffaroni N, et al. Pazopanib in advanced and platinumresistant urothelial cancer: An open-label, single group, phase 2 trial. Lancet Oncol 2012; 13:810-6
4. Ko YJ, Canil CM, Mukherjee SD, et al. Nanoparticle albumin-bound paclitaxel for second-line treatment of metastatic urothelial carcinoma: A single group, multicentre, phase 2 study. Lancet Oncol 2013; 14:769-76
5. Wong YN, Litwin S, Vaughn D, et al. Phase II trial of cetuximab with or without paclitaxel in patients with advanced urothelial tract carcinoma. J Clin Oncol 2012; 30:3545-51
6. Choueiri TK, Ross RW, Jacobus S, et al. Double-blind, randomized trial of docetaxel plus vandetanib versus docetaxel plus placebo in platinum-pretreated metastatic urothelial cancer. J Clin Oncol 2012; 30:507-12
7. Bellmunt J, Choueiri TK, Fougeray R, et al. Prognostic factors in patients with advanced transitional cell carcinoma of the urothelial tract experiencing treatment failure with platinum-containing regimens. J Clin Oncol 2010; 28:1850-5
8. Sonpavde G, Pond GR, Fougeray R, et al. Time from previous chemotherapy enhances prognostic risk grouping in the second-line setting of advanced urothelial carcinoma: A retrospective analysis of pooled, prospective phase 2 trials. Eur Urol 2013; 63:717-23
9. Pond GR, Agarwal N, Bellmunt J, et al. A nomogram including baseline prognostic factors to estimate the activity of second-line therapy for advanced urothelial carcinoma. BJU Int 2014; 113:E137-43
10. Agarwal N, Bellmunt J, Maughan BL, et al. Six-month progression-free survival as the primary endpoint to evaluate the activity of new agents as second-line therapy for advanced urothelial carcinoma. Clin Genitourin Cancer 2014; 12: 130-7
11. Pond GR, Bellmunt J, Fougeray R, et al. Impact of response to prior chemotherapy in patients with advanced urothelial carcinoma receiving second-line therapy: Implications for trial design. Clin Genitourin Cancer 2013; 11:495-500
12. Sonpavde G, Bellmunt J, Rosenberg JE, et al. Impact of number of lines of previous chemotherapy in patients (pts) with advanced urothelial carcinoma (UC) receiving salvage therapy. Paper presented at: The Genitourinary Cancer Symposium 2014; January 19-February 1; San Francisco, CA
13. Harshman LC, Fougeray R, Choueiri TK, et al. The impact of previous platinum therapy on survival in patients with metastatic urothelial cancer receiving vinflunine. Br J Cancer 2013; 109:2548-53
14. Sonpavde G, Bellmunt J, Rosenberg JE, et al. Impact of previous platinum agent and site of primary in patients with advanced urothelial carcinoma (UC) receiving salvage therapy. Paper presented at: The Genitourinary Cancer Symposium 2014; January 19-February 1; San Francisco, CA
15. Bellmunt J, von der Maase H, Mead GM, et al. Randomized phase III study comparing paclitaxel/cisplatin/gemcitabine and gemcitabine/cisplatin in patients with locally advanced or metastatic urothelial cancer without previous systemic therapy: EORTC Intergroup Study 30987. J Clin Oncol 2012; 30: 1107-13
16. Galsky MD, Moshier E, Krege S, et al. Nomogram for predicting survival in patients with unresectable and/or metastatic urothelial cancer who are treated with cisplatin-based chemotherapy. Cancer 2013; 3012-9
17. von der Maase H, Hansen SW, Roberts JT, et al. Gemcitabine and cisplatin versus methotrexate, vinblastine, doxorubicin, and cisplatin in advanced or metastatic bladder cancer: Results of a large, randomized, multinational, multicenter, phase III study. J Clin Oncol 2000; 18:3068-77
18. De Santis M, Bellmunt J, Mead G, et al. Randomized phase II/III trial assessing gemcitabine/carboplatin and methotrexate/carboplatin/vinblastine in patients with advanced urothelial cancer who are unfit for cisplatinbased chemotherapy: EORTC study 30986. J Clin Oncol 2012; 30: 191-9
19. Galsky MD, Chowdhury S, Bellmunt J, et al. Treatment patterns and outcomes in "real world" patients with metastatic urothelial cancer. J Clin Oncol 2013; 31(suppl), abstract 4525.